Cutaneous T-Cell Lymphoma

Please answer the questions with references

Akachi Chizoba is a 51 year old male is here today with complaints that the “contact dermatitis” that he was diagnosed with in Unit 1 has not yet resolved. He is very worried because this is very unusual for him. Based on the persistent rash and concern expressed by Akachi, you refer Akachi to dermatology. Dermatology performed a skin biopsy. The skin biopsy showed cutaneous t-cell lymphoma. As soon as you receive these results, you immediately call Akachi. You will refer to Akachi to Oncology however you want to be prepared in order to discuss the next steps of his management.

Questions:

1. What are non-pharmacologic treatment strategies for the management of cutaneous t-cell lymphoma?

2.Based on the current clinical practice guidelines, what pharmacologic treatment do you suspect the oncologist would you prescribe Akachi (be sure to include, at a minimum, drug name, dose, route, frequency)?

3. What is the mechanism of action of the selected pharmacologic agent? How does the mechanism of action correlate with the physiology/pathophysiology of cutaneous t-cell lymphoma?

4.What are the most common adverse effects the selected pharmacologic agent?

5. What is the cost of the selected pharmacologic agent?

6. Discuss pharmacokinetics and pharmacodynamics of the selected pharmacologic agent (be sure to include, at a minimum, onset, peak, duration, half-life, etc).